Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;42(3):153-6.
doi: 10.4103/0253-7613.66838.

Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension

Pramod B Akat  1 , Tushar R Bapat, Mangala B Murthy, Vitthal B Karande, Shreyas R Burute
Affiliations

Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension

Pramod B Akat et al. Indian J Pharmacol. 2010 Jun.

Abstract

Background: Theoretically, angiotensin II receptor blockers (ARBs) have certain advantages over angiotensin-converting enzyme inhibitors, but the contribution of these advantages to the clinical effect of ARBs is not known.

Objective: To compare the efficacy and tolerability of telmisartan with enalapril in patients of essential hypertension.

Materials and methods: Patients of mild to moderate hypertension were randomized to receive either 40 mg of telmisartan or enalapril 10 mg once a day orally for 12 weeks. At each visit, the systolic blood pressure (BP), diastolic BP and heart rate of each patient were recorded. Investigations such as hemogram hemoglobin, total leucocytes count (Hb, TLC), serum creatinine, serum glutamic oxaloacetic transaminase, serum glutamic pyruric transaminase (SGOT, SGPT) random blood sugar and urine examination were performed at baseline and after 12 weeks of the treatment period.

Results: The mean reduction in systolic BP in the telmisartan/enalapril group was 26.38 ± 10.98/26.74 ± 8.24 mmHg while the mean reduction in diastolic BP in the telmisartan/enalapril group was 14 ± 2.98/9.71 ± 4.23 mmHg, respectively, at 12 weeks. When the reduction in systolic BP in the two groups was compared, there was no significant difference between the groups (P > 0.05). However, the mean reduction in diastolic BP achieved with telmisartan at 12 weeks was significantly higher (P < 0.001) than that achieved with enalapril after the corresponding period. The overall frequency of adverse-effects was similar. However, in the enalapril group, the incidence of dry cough was higher as compared to that in the telmisartan group (11.43% vs. 0%, respectively; P < 0.05).

Conclusion: Telmisartan produces a greater reduction in diastolic BP than enalapril and is free from the adverse-effect of dry cough that is commonly encountered with enalapril.

Keywords: Blood pressure; diastolic BP; enalapril; hypertension; systolic BP; telmisartan.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

References

    1. Jackson EK. Renin and angiotensin. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilmans The Pharmacological Basis of Therapeutics. 11th ed. New York: Mc Graw Hill Medical Publishing division; 2006. pp. 789–821.
    1. Ball SG, White WB. Debate: Angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine. Am J Cardiol. 2003;91:15G–21G. - PubMed
    1. Battershill AJ, Scott LJ. Telmisartan: A review of its use in the management of hypertension. Drugs. 2006;66:51–83. - PubMed
    1. Amerena J, Pappas S, Ouellet JP, Williams L, O’Shaughnessy D. ABPM comparison of the antihypertensive profiles of telmisartan and enalapril in patients with mild to moderate essential hypertension. Int Med Res. 2002;30:543–52. - PubMed
    1. Chen JH, Cheng JJ, Chen CY, Chiou HC, Huang TY, Tsai CD, et al. Comparison of the efficacy and tolerability of telmisartan 40 mg vs.enalapril 10 mg in the treatment of mild-to-moderate hypertension: A multicentre, double-blind study in Taiwanese patients. Int J Clin Pract Suppl. 2004;145:29–34. - PubMed